Should we ignore SARS-CoV-2 disease?
Current World Health Organization (WHO) reports claim a decline in COVID-19 testing and reporting of new infections. To discuss the consequences of ignoring severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, the endemic characteristics of the disease in 2023 with the ones estimated before using 2022 data sets are compared. The accumulated numbers of cases and deaths reported to the WHO by the 10 most infected countries and global figures were used to calculate the average daily numbers of cases DCC and deaths DDC per capita and case fatality rates (CFRs = DDC/DCC) for two periods in 2023. In some countries, the DDC values can be higher than the upper 2022 limit and exceed the seasonal influenza mortality. The increase in CFR in 2023 shows that SARS-CoV-2 infection is still dangerous. The numbers of COVID-19 cases and deaths per capita in 2022 and 2023 do not demonstrate downward trends with the increase in the percentages of fully vaccinated people and boosters. The reasons may be both rapid mutations of the coronavirus, which reduced the effectiveness of vaccines and led to a large number of re-infections, and inappropriate management.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:152 |
|---|---|
| Enthalten in: |
Epidemiology and infection - 152(2024) vom: 20. März, Seite e57 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nesteruk, Igor [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.04.2024 Date Revised 25.04.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1017/S0950268824000487 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369958306 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369958306 | ||
| 003 | DE-627 | ||
| 005 | 20240425233224.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240320s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1017/S0950268824000487 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM369958306 | ||
| 035 | |a (NLM)38506229 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nesteruk, Igor |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Should we ignore SARS-CoV-2 disease? |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.04.2024 | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Current World Health Organization (WHO) reports claim a decline in COVID-19 testing and reporting of new infections. To discuss the consequences of ignoring severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, the endemic characteristics of the disease in 2023 with the ones estimated before using 2022 data sets are compared. The accumulated numbers of cases and deaths reported to the WHO by the 10 most infected countries and global figures were used to calculate the average daily numbers of cases DCC and deaths DDC per capita and case fatality rates (CFRs = DDC/DCC) for two periods in 2023. In some countries, the DDC values can be higher than the upper 2022 limit and exceed the seasonal influenza mortality. The increase in CFR in 2023 shows that SARS-CoV-2 infection is still dangerous. The numbers of COVID-19 cases and deaths per capita in 2022 and 2023 do not demonstrate downward trends with the increase in the percentages of fully vaccinated people and boosters. The reasons may be both rapid mutations of the coronavirus, which reduced the effectiveness of vaccines and led to a large number of re-infections, and inappropriate management | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Brazil | |
| 650 | 4 | |a COVID-19 epidemic dynamics in USA | |
| 650 | 4 | |a COVID-19 mortality | |
| 650 | 4 | |a COVID-19 pandemic | |
| 650 | 4 | |a China | |
| 650 | 4 | |a France | |
| 650 | 4 | |a Germany | |
| 650 | 4 | |a India | |
| 650 | 4 | |a Italy | |
| 650 | 4 | |a Japan | |
| 650 | 4 | |a South Korea | |
| 650 | 4 | |a UK | |
| 650 | 4 | |a endemic characteristics of SARS-CoV-2 | |
| 650 | 4 | |a mathematical modelling of infectious diseases | |
| 650 | 4 | |a statistical methods | |
| 650 | 7 | |a Influenza Vaccines |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Epidemiology and infection |d 1992 |g 152(2024) vom: 20. März, Seite e57 |w (DE-627)NLM012620912 |x 1469-4409 |7 nnns |
| 773 | 1 | 8 | |g volume:152 |g year:2024 |g day:20 |g month:03 |g pages:e57 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1017/S0950268824000487 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 152 |j 2024 |b 20 |c 03 |h e57 | ||